Chymase is a unique, abundant secretory product of mast cells and a potent chemoattractant for eosinophils, monocytes and neutrophils, but little is known of its influence on mast cell accumulation.
Introduction
Chymase is a mast cell serine proteinase with a molecular weight of 30 kDa. It is exclusively located in the granules of mast cells together with tryptase, histamine, heparin, cytokines and other products (Schwartz, 1994) . Since a large quantity of the active form of chymase is released by mast cells, into their adjacent environment, upon degranulation (He et al., 1999) , it is likely to play a role in mast cell-related diseases such as allergy. Indeed, it has been recently reported that airway higher responsiveness to mannitol in asthma is associated with chymase-positive mast cells (Sverrild et al., 2016) .
Chymase has been reported to be a potent chemoattractant for eosinophils (He and Walls, 1998a) via an ERK and p38 MAPK-mediated mechanism (Terakawa et al., 2005) . It is also a chemoattractant for monocytes and neutrophils (Tani et al., 2000) . The finding that chymase inhibitors reduced the increase in the number of dermal mast cells in 2, 4-dinitrofluorobenzene-induced dermatitis and that intradermal injection of human chymase significantly increased the histamine content in skin suggests that chymase released by mast cells may participate in local mast cell accumulation (Tomimori et al., 2002a) . However, little is known of the potential mechanisms of chymase-induced mast cell accumulation.
Apart from its direct influence on mast cell accumulation, chymase may induce mast cell accumulation via indirect mechanisms. Since chymase can provoke mast cell degranulation (He et al., 1999) and induce the release of IL-8 from human EoL-1 cells (Terakawa et al., 2006) , it may very likely induce the release of other mast cell products such as 5-HT (serotonin) (Wong et al., 2002) , eotaxin (CCL11) and regulated upon activation, normal T-cell-expressed and -secreted (RANTES; CCL5) (Shakoory et al., 2004) from mast cells upon activation. Moreover, it has been found that sumatriptan, a 5-HT receptor agonist, enhanced thalamic mast cell population, especially those containing 5-HT (Dubayle et al., 2005) , and that RANTES can provoke a strong recruitment of mast cells selectively in rats (Conti et al., 1998) , implicating the involvement of mast cell secretory products in mast cell accumulation. The aim of the current study was to investigate the ability of chymase to induce mast cell accumulation and the potential mechanisms involved in this effect.
Methods

Animals, cell line and culture
Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . BALB/c mice (6-8 weeks) and C57BL/6J mice (6) (7) (8) 
Preparation of enzymes
Human chymase was purified from human skin tissue obtained at circumcision by high salt extraction, heparin agarose and S-200 sephacryl gel filtration chromatography procedures as described previously (He and Walls, 1998a was evaluated using 10% SDS-PAGE, and the identity of the protein band was confirmed by Western blotting with a monoclonal antibody CC1 against human chymase. Chymase prepared for this study had a single diffuse band on SDS-PAGE. There was no elastolytic activity and negligible tryptase contamination in this preparation. As chymase is enzymatically unstable in physiological solutions, considerable care was taken in its preparation. Purified chymase stored in high salt buffer was diluted immediately prior to its injection, first with sterile distilled water, adjusting the NaCl concentration to 0.15 mol·L À1 , and then with normal saline (NS) to obtain the required chymase concentration. Human serum albumin (HSA) in saline was used as a foreign protein control. Where added, proteinase inhibitors or drugs were incubated with chymase for 30 min on ice before injection. Tryptase was purified from human lung tissues by high salt extraction, heparin agarose and immunoaffinity chromatography procedures with monoclonal antibody AA5 against tryptase as described previously (He et al., 1997) . The specific activity of the tryptase used in these studies was 1.96 U·mg À1 .
The preparation had no detectable chymotryptic or elastolytic activity, and endotoxin levels were very low, being less than 49 pg·mg À1 tryptase.
Mouse i.p. injection and cell count
The procedure was adapted from that described previously (He et al., 1997 of 5-HT. Control animals received an equivalent dose of the corresponding normal rat or hamster IgG isotype control or drug alone. At 6 h following injection, the mice were killed and their peritoneal lavages were processed as described above.
Trans-endothelial migration of mast cells in vitro
To further investigate the effect of chymase on mast cell migration, a co-culture system with HMC-1 and HMEC-1 cells was established. The migration of HMC-1 cells was assessed by using E-16-well plates and the xCELLigence technology (Acea Bioscience, San Diego, CA, USA) (Limame et al., 2012) . Briefly, 165 μL medium solutions containing N-formylmethionyl-leucyl-phenylalanine (fMLP) alone at 10 μM or chymase at 0, 0. 
Flow cytometry analysis of mast cells and endothelial cells
Cells in lower chambers were collected in 1 mL of 1% BSA/PBS and pelleted by centrifugation. This was followed by incubation of cells with PE-conjugated anti-human CD117 antibody at room temperature for 15 min in the dark. PE-conjugated mouse IgG1 was used as an isotype control. After being washed, cells were resuspended in FACS-Flow solution and analysed with a FACS Verse flow cytometer with FlowJo software version 7.0 (Treestar, Ashland, USA).
ELISA
Levels of mouse mast cell chymase 1 (CAM-1), 5-HT, eotaxin and RANTES were measured by using ELISA kits according to the manufacturer's instruction.
Statistics
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Statistical analyses were performed by using SPSS software (version 21.0, IBM Corporation). Data are displayed as a boxplot, which indicates the median, interquartile range, the largest and smallest values for the number of experiments indicated. Where Kruskal-Wallis analysis indicated significant differences between groups, a pairwise test was used for multiple comparisons between the groups. Data for trans-endothelial migration of HMC-1 cells are expressed as mean ± SEM. Where ANOVA indicated significant differences between groups with ANOVA, a Bonferroni method was applied for further comparison. For all analyses, P < 0.05 was considered statistically significant.
Materials
The following compounds were purchased from SigmaAldrich (St Louis, MO, USA): human α 1 -antitrypsin, human α 1 -antichymotrypsin, human chymotrypsin, mouse SLPI, SBTI, chymostatin, CI A23187, fMLP, mouse eotaxin, mouse RANTES, sodium cromoglycate, terfenadine, SAAPP, 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017) .
Results
CI-induced mast cell accumulation and chymase release in the peritoneum of mice
We recently reported that the mast cell secretagogue compound 48/80 is a potent stimulus of mast cell accumulation (Liu et al., 2016) . Therefore, it is likely that CI, a mast cell activator, can also induce mast cell recruitment. To further confirm the concept that mast cell degranulation may provoke mast cell accumulation in vivo, we investigated the ability of CI to induce mast cell accumulation in a mouse peritoneal inflammation model. The result showed that CI induced a dosedependent mast cell accumulation in mouse peritoneum at 6 h ( Figure 1A ) and 16 h ( Figure 1B ) following injection. As little as 0.01 μM CI was capable of inducing up to approximately 86% increase in mast cell accumulation in mouse peritoneum at 16 h following injection. Up to 1.4-fold increase in accumulation of mast cells was achieved when 1.0 μM of CI was injected for 16 h. It was observed that chymase inhibitors α 1 -antitrypsin, SBTI and SLPI, inhibited CI-induced mast cell accumulation by up to 100 and 88.5%, 81.3 and 100% and 94.5 and 98.6% at 6 and 16 h following injection, respectively, indicating that the unique mast cell granule product chymase may contribute to CI-induced mast cell accumulation. In order to confirm that CI-induced accumulation of mast cells is via the release of endogenous chymase from mast cells, we examined the levels of chymase in the peritoneum of mouse following CI administration. The results showed that CI at 0.3 and 1.0 μM provoked up to 44% increase in production of mouse mast cell chymase 1 in mouse peritoneum following 3 and 6 h injection ( Figure 1C ).
Induction of mast cell accumulation by chymase and α 1 -chymotrypsin
We recently reported that tryptase is potent at inducing chemotaxis of mast cells (Liu et al., 2016) , which suggests a self-amplification mechanism of mast cell accumulation. Since chymase and tryptase are both located in the secretory granules of mast cells (Schwartz et al., 1987) , we anticipated that chymase may also have the ability to elicit mast cell accumulation. It was found that chymase induced dose-dependent mast cell accumulation in the peritoneum of mice following 10 min, 3, 6 and 16 h injection (Figure 2) . Chymase provoked mast cell accumulation initiated at 10 min following injection ( Figure 2D ) and lasted at least to 16 h ( Figure 2F ). As little as 0.005 μg of chymase was capable of eliciting marked mast cell accumulation at 3 h following injection, and the maximum of 5.4-fold increase in mast cells was achieved when 5.0 μg of chymase was injected for 3 h ( Figure 2D ).
Since chymase belongs to the chymotrypsin family of protease (Sukenaga et al., 1993) and chymase-induced mast cell accumulation may depend on its enzymatic activity, we employed the common chymotryptic enzymes α 1 -chymotrypsin (Niemann, 1964) and elastase as positive and negative controls, respectively, in the present study. The results showed that α 1 -chymotrypsin also induced a dose-dependent increase in mast cell accumulation at 6 h ( Figure 2E ) and 16 h ( Figure 2F ) following injection. As little as 0.05 μg of α 1 -chymotrypsin was able to elicit marked mast cell accumulation at 16 h following injection, and the maximum of 1.2-fold increase in mast cells was achieved when 5.0 μg of α 1 -chymotrypsin was injected for 16 h ( Figure 2F ). These results suggest that chymase-induced mast cell accumulation is likely to be as results of its enzymatic activity. In contrast, elastase failed to provoke mast cell accumulation at 3, 6 and 16 h following injection.
Inhibitors of chymase including α 1 -antichymotrypsin, chymostatin, SBTI, SLPI and ZIGPFM suppressed chymaseinduced mast cell accumulation by up to 93.8, 95.9, 53.1, 59.9 and 90.5% respectively, whereas heat-inactivating chymase (56°C for 120 min) abolished up to 89.1% of its ability to accumulate mast cells ( Table 1 ), confirming that chymase-induced mast cell accumulation is dependent on its enzymatic activity. Similarly, α 1 -antichymotrypsin reduced α 1 -chymotrypsin-induced mast cell accumulation by up to 98.8% at 6 h following injection. These inhibitors by themselves did not alter the number of mast cells in the peritoneum of mice when injected alone (data not shown).
In order to further confirm the abilities of chymase and CI to induce mast cell accumulation, mast cell-deficient (Kit W-4Bao ) and wild-type C57BL/6J mice were employed.
The result showed that chymase at 0.5 μg and CI at 1.0 μM induced up to 1.69-fold and 0.85-fold increase in peritoneal mast cells in wild-type C57BL/6J mice at 6 h following injection ( Figure 2G ). Mast cell-deficient mice did not show any mast cells in their peritoneum.
Influence of tryptase on chymase-induced mast cell accumulation
Tryptase and chymase are released from mast cells at the same time upon mast cell degranulation and possibly from the same granules (Schwartz, 1990) . Therefore, they may have a mutual effect on their ability to accumulate mast cells. To investigate this possible interaction, we determined the
Figure 1
Mast cell accumulation and chymase production in the peritoneum of mice induced by CI A23187 (μM). Various concentrations of CI in the presence or absence of α 1 -antitrypsin (Antitryp, μg), SBTI (μg) and SLPI (μg) were injected i.p. in mice for 6 h (A) and 16 h (B). Various concentrations of CI were injected for 3 and 6 h before their peritoneal lavage fluids were collected for chymase measurement (C). Normal saline (NS) was employed as a vehicle. Data are displayed as a boxplot, which indicates the median, interquartile range, the largest and smallest values. Each group of data represents results from six to seven animals. *P < 0.05 compared with the corresponding NS group. † P < 0.05 compared with the corresponding stimulus alone group.
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influence of tryptase on chymase-induced mast cell accumulation in the present study. The results show that tryptase at 0.5 μg had an additive effect on 5.0 μg chymaseinduced mast cell accumulation at 6 h ( Figure 2E ) and on 0.5 μg chymase-induced mast cell accumulation at 16 h ( Figure 2F ) following injection. 
Induction of trans-endothelium migration of mast cells in vitro by chymase
It is reported that human tryptase can induce transendothelium migration of mast cells in vitro (Liu et al., 2016) , indicating that tryptase is a potent chemoattractant of mast cells. In order to understand the mechanism of chymase-induced mast cell accumulation, we investigated the ability of chymase to induce the trans-endothelium migration of mast cells in vitro. The results show that chymase induced up to 46.2% increase in migration of mast cells. An anti-ICAM-1 antibody, chymostatin and SBTI completely abolished chymase-induced mast cell migration (Figure 3) , suggesting that the action of chymase was mediated by ICAM-1 and dependent on its enzymatic activity.
Figure 3
The trans-endothelium migration of mast cells in vitro induced by chymase. Various concentrations of chymase (μg·mL À1 ) with or without chymostatin (1.0 μg·mL À1 ) or SBTI (1.0 μg·mL À1 ) were added to chambers of E-16-well plates, respectively, and incubated for 1 h. Anti-human ICAM-1 antibody (Anti-ICAM-1, 50 μL of 10 μg·mL À1 solution) was added to specified wells and cultured for 15 min. Cells in the lower chamber were collected for flowcytometric analysis of HMC-1 mast cells. fMLP (10 μM) was used as a positive control. Values shown are mean ± SEM for four independent experiments. *P < 0.05 compared with the response to medium alone control group. † P < 0.05 compared with the response to the corresponding stimulus alone group. 
Effect of anti-ICAM-1, anti-L-selectin, anti-CD11a and anti-CD18 antibodies and drugs on chymase-induced mast cell accumulation
In order to further understand the mechanism of chymaseinduced mast cell accumulation, we investigated the effect of adhesion molecules on chymase-induced mast cell accumulation in the peritoneum of mice. The results show that anti-CD11a, anti-CD18, anti-L-selectin, anti-ICAM-1 antibodies, sodium cromoglycate and terfenadine inhibited chymase provoked mast cell accumulation by 85.2, 81.5, 84.8, 74.1, 81.5 and 74.8%, respectively, when they were i.v. injected into mice, suggesting that chymase-elicited mast cell accumulation was dependent upon the activities of the CD11a/CD18 complex, L-selectin and ICAM-1 (Figure 4 ).
Effect of chymase on mast cell-derived 5-HT and eotaxin release in the peritoneum of mice
Since inhibitors of chymase did not completely abolish chymase-induced mast cell accumulation and migration, it is possible that chymase may provoke mast cell accumulation through some indirect mechanisms. It has been reported previously that chymase is capable of inducing mast cell degranulation (He et al., 1998) ; we therefore investigated the ability of chymase to induce the release of mast cell-derived 5-HT, eotaxin and RANTES in the peritoneal lavage of mice. The results show that chymase at 0.5 μg increased, by up to 1.8-fold, 5-HT release in the peritoneum of BALB/C mice, which is comparable to that induced by CI at 3 h following injection ( Figure 5A ). Similarly, chymase provoked up to 3.2-fold eotaxin increase ( Figure 5B ) but had little effect on level of RANTES in mouse peritoneum (data not shown). Chymostatin (5 μg) suppressed chymase-induced 5-HT release by 88.6% and completely abolished chymase-induced eotaxin release ( Figure 5B ). 5-HT at 0.5 μg appeared to be more potent than chymase at inducing the production of eotaxin. It increase the production of by more than 3.2-fold in mouse peritoneum. It was observed that 5-HT-induced production of eotaxin was almost completely abolished by its inhibitor WAY100635 ( Figure 5B ). Chymase at 0.5 μg also increased the release of 5-HT ( Figure 5C ) and eotaxin ( Figure 5D ) in wild-type C57BL/6J mice. Compared with wild-type C57BL/6J mice, mast cell-deficient (Kit W-4Bao ) mice had low 5-HT ( Figure 5C ) and eotaxin ( Figure 5D ) levels in their peritoneum. Chymase had little effect on 5-HT ( Figure 5C ) and eotaxin ( Figure 5D ) levels in mast cell deficient (Kit W-4Bao ) mice.
Induction of mast cell accumulation by chemokines
5-HT is used as an indicator of mouse mast cell degranulation (Krop et al., 2010) , but little is known of its ability to induce mast cell accumulation. After confirmation that chymase can provoke increased 5-HT and eotaxin release in mouse peritoneum, the next issue that should be addressed is whether 5-HT and these chemokines have the ability to provoke mast cell accumulation. We therefore investigated the effect of 5-HT, eotaxin and RANTES on mast cell accumulation in mouse peritoneum. The results showed that 5-HT at 0.5 μg induced dramatic mast cell accumulation in mouse peritoneum, which could be inhibited by WAY100635 at 10 μg ( Figure 6A ). Eotaxin induced marked mast cell accumulation in peritoneum of mice at 3, 6 and 16 h following injection ( Figure 6B ). As little as 0.05 ng eotaxin induced up to 1.4-fold increase in mast cell number at 3 h following injection. The maximum increase in mast cell number, 3.2-fold, was provoked by 5.0 ng eotaxin at 16 h following injection ( Figure 6B) . Similarly, 0.05 ng RANTES elicited up to 1.3-fold increase in mast cell number at 3 h following injection. The
Figure 4
Inhibition of mast cell accumulation by antibodies against cell adhesion molecules and drugs. Mice were pretreated with a monoclonal antibody against either L-selectin (anti-CD62L), CD11a (anti-CD11a), CD18 (anti-CD18) or ICAM-1 (anti-CD54), respectively (all at a dose of 1 mg·kg À1 ), or with sodium cromoglycate (Cromogl, 20 mg·kg À1 ) or terfenadine (Terf, 2 mg·kg À1 ) for 30 min before i.p. injection of chymase (0.5 μg) for 6 h. NS was employed as a vehicle. Data were displayed as a boxplot, which indicates the median, interquartile range, the largest and smallest values. Each data group represents results from six and seven animals. *P < 0.05 compared with the NS group. † P < 0.05 compared with chymase alone group.
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maximum increase in mast cell number, 3.9-fold, was provoked by 5.0 ng RANTES at 16 h following injection ( Figure 6C ).
Effect of anti-ICAM-1, anti-L-selectin, anti-CD11a and anti-CD18 antibodies and drugs on chemokine-induced mast cell accumulation
In order to understand the migration mechanism of the chemokine-induced mast cell accumulation, we investigated the effect of adhesion molecules, sodium cromoglycate and terfenadine on eotaxin-and RANTES-induced mast cell accumulation in the peritoneum of mice. The results show that eotaxin-induced mast cell accumulation was inhibited by pretreatment with anti-L-selectin antibody (injected i.v.), and RANTES-elicited mast cell infiltration was suppressed by pretreatment with anti-CD11a, anti-CD18 and anti-CD54 antibodies (injected i.v.) ( Figure 7A ). Pretreatment of mice with sodium cromoglycate or terfenadine for 30 min before peritoneal injection of eotaxin or RANTES completely abolished eotaxin-or RANTES-induced mast cell accumulation in the peritoneum of mice ( Figure 7B ).
Discussion
As for compound 48/80, CI is a potent mast cell degranulator. Thus, CI-induced mast cell accumulation is most likely Figure 5 The release of 5-HT and eotaxin induced by chymase in the peritoneum of mice. (A) Various concentrations of chymase in the presence or absence of chymostatin (Chymos, 5 μg), elastase (μg) or CI A23187 (μM) were injected i.p. 10 min and 3 h before the peritoneal lavage fluids were collected for 5-HT measurement. (B) Various concentrations of chymase in the presence or absence of chymostatin (Chymos, 5 μg), 5-HT (μg) in the presence or absence of WAY100635 (μg) or elastase (μg) were injected i.p. 10 min and 3 h before the peritoneal lavage fluids were collected for eotaxin measurement. Chymase (μg) and CI (μM) were injected i.p. in wild-type C57BL/6J mice and mast cell-deficient (Kit W-4Bao ) mice before peritoneal levels of 5-HT (C) or eotaxin (D) were determined. NS was employed as a vehicle. Data are displayed as a boxplot, which indicates the median, interquartile range, the largest and smallest values. Each data group represents the results from six to seven animals. *P < 0.05 compared with the corresponding NS group. † P < 0.05 compared with the corresponding stimulus alone group.
mediated by mast cell products released upon degranulation. Among mast cell granule products, tryptase (Liu et al., 2016) and histamine (Hofstra et al., 2003) have been found to provoke mast cell accumulation. Since both tryptase and histamine can activate mast cells and can be released from mast cells, a unique self-amplification mechanism of mast cell infiltration and activation was previously proposed (He et al., 2012) . As a major mast cell granule product, chymase may also have ability in induction of mast cell accumulation. Marked inhibition of CI-induced mast cell accumulation by inhibitors of chymase and CI-provoked production of mouse mast cell chymase 1 indicate that chymase is also likely to participate in mast cell accumulation in the peritoneum of mice. Indeed, the current study demonstrates for the first time that chymase is a potent chemoattractant for mast cells. Since chymase can induce mast cell degranulation (He and Walls, 1998b) , the current finding that chymase provokes mast cell infiltration proposes a novel self-amplification mechanism of mast cell accumulation. Since airway higher responsiveness to mannitol in asthma is associated with chymase-positive mast cells (Sverrild et al., 2016) , chymase modulates IL-33 levels and controls allergic sensitization in house-dust-mite-induced airway inflammation (Waern et al., 2013) , and chymase contributes to the pathogenesis of chronic dermatitis (Tomimori et al., 2002b) , our current finding ought to be important in understanding the mechanisms of chymase-related inflammatory diseases, including allergy.
It seems likely that chymase-induced mast cell accumulation depends on its enzymatic activity as several inhibitors of chymase hydrolytic activity blocked chymase actions on mast cell migration. Chymase chemotactic activity appears to also rely on its intact catalytic site, as heat-inactivation of the enzyme resulted in almost complete loss of its ability to induce mast cell recruitment. The enzymatic activitydependent function of chymase has been previously observed. For example, α 1 -chymotrypsin, chymostatin, SBTI, SLPI and ZIGPFM suppressed chymase-induced neutrophil and macrophage accumulation in the mouse peritoneum (He et al., 2004) . Also, natural and synthetic chymase inhibitors eliminated histamine release from human mast cells ex vivo (Dietze et al., 1990) . Another piece of evidence demonstrating that enzymatic activity is required for chymaseinduced mast cell migration is that α 1 -chymotrypsin can also induce mast cell activation; they both belong to chymotrypsin family of proteases. Since α 1 -chymotrypsin and chymase have a similar potency at inducing mast cell accumulation, we believe further that the action of chymase is dependent on its enzymatic activity.
It is likely that ICAM-1 is a key adhesion molecule for chymase-induced mast cell migration as it mediates the migration of these cells both in vivo and in vitro. The findings that ICAM-1-mediated mast cell migration has been observed in IL-29-induced mast cell accumulation (He et al., 2010) and that L-selectin or ICAM-1 deficiency reduces an immediatetype hypersensitivity response by preventing mast cell recruitment (Shimada et al., 2003) supports the view that ICAM-1 plays a key role in mast cell accumulation. L-selectin also appears to be an important adhesion molecule for mast cell migration as it not only mediates chymase-induced mast cell accumulation but also regulates mast cell recruitment in immediate-type hypersensitivity response in a mouse model of contact atopic dermatitis (Shimada et al., 2003) . Furthermore, the CD11a/CD18 complex seems to participate in chymase-induced mast cell migration as anti-CD11a and anti-CD18 antibodies inhibited the action of chymase. Since anti-CD11a and anti-CD18 antibodies can suppress tryptaseinduced mast cell accumulation as well (Liu et al., 2016) , it seems likely that the CD11a/CD18 complex plays an important role in protease-induced mast cell accumulation.
The similar adhesion mechanisms involved in tryptaseand chymase-provoked mast cell infiltration and the fact that trypase and chymase are released together from degranulated mast cells (Schwartz, 1990) indicate that there may be interactions between these two major mast cell granule products. Indeed, the additive or even synergistic interactions between tryptase and chymase were observed in the present study, which suggests that there must be some different adhesion and migration mechanisms involved in tryptase-or chymase-induced mast cell accummulation. Obviously, more work is required to address this issue further.
It is reported that chymase induces release of stem cell factor (SCF) from human keratinocytes; the soluble SCF released then provokes mast cell accumulation (Nilsson et al., 1994) . Similarly, chymase has been found to elicit IL-8 release from eosinophils (Wong et al., 2009) , and IL-8 can recruit mast cells through CXCR1 (Lippert et al., 1998) and CXCR2 (Nilsson et al., 1999) receptors on the surface of HMCs. RANTES can be released from mast cells (Shakoory et al., 2004) , and RANTES is chemotactic for mast cells (Nilsson et al., 1994; . Previously, little was known of the influence of eotaxin on mast cell migration, but our current observations provide a clear message that eotaxin is probably a chemokine for mast cells. Similar to its effect on monocytes and neutrophils (Tani et al., 2000) , chymase showed potent chemotactic activity for mast cells. The potency of chymase at inducing the trans-endothelium migration of mast cells was comparable to that of fMLP. A report that 5-HT levels and the density of mast cells in the inflamed colon was higher than in controls suggests that the increase in 5-HT levels in 2,4,6-trinitrobenzene sulfonic acid (TNBS) -induced colitis may result from infiltrated mast cells (Magro et al., 2006) . Sumatriptan, a 5-HT receptor agonist, enhanced thalamic mast cell population, especially those containing 5-HT (Dubayle et al., 2005) , indicating that mast cells containing 5-HT-and 5-HT-induced mast cell accumulation is mediated by its receptor. Taken together the fact that chymase induces 5-HT release and mast cell accumulation and that both mouse and HMCs respond to 5-HT through the 5-HT 1A receptor (Kushnir-Sukhov et al., 2006) , it is likely that 5-HT contributes to chymase-induced mast cell accumulation.
Inhibition of chymase-induced mast cell accumulation by sodium cromoglycate may result from inhibition of the expression of ICAM-1, as sodium cromoglycate is reported to be able to reduce mast cell numbers and expression of ICAM-1 in bronchial mucosa of asthmatics (Hoshino and Nakamura, 1997) . In contrast, inhibition of chymaseinduced mast cell accumulation by terfenadine could be due to the inhibitory activity of terfenadine on anti-IgE-induced mediator release from lung and skin mast cells (Massey et al., 1993) and inhibition of ICAM-1 expression on epithelial cells (Ciprandi et al., 2003) .
It should be noted that the chymase used in the mouse peritoneal experiments was human skin chymase. The amino acid identity between human chymase (UniProtKB -P23946) and murine chymase (UniProtKB -P21844) is 74.1%. In order to exclude the influence of foreign protein on mast cell accumulation, HSA was employed as a negative foreign protein control. The neglible effect of HSA on mast cell accumulation in mouse peritoneum supports that the postulate that the ability of chymase to induce mast cell accumulation is not related to it being a foreign protein.
In conclusion, chymase-induced mast cell accumulation appears through a CD11a/CD18 complex, L-selectin and ICAM-1-dependent mechanism and relies on its enzymatic activity. 5-HT and eotaxin production from mast cells may also be involved in the event. The induction of mast cell accumulation by chymase implies further that chymase ought to be considered a major pro-inflammatory mediator of mast cells. The provocation of mast cell accumulation by the major granule product of mast cells, chymase, suggests a novel selfamplification mechanism for mast cell accumulation in allergic inflammation. Mast cell stabilizers as well as inhibitors of chymase may have potential as a treatment of allergic disorders.
